Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement
Advertisement

ASCO 2022: Mobocertinib Versus Amivantamab-vmjw in Treatment of EGFR-Mutated NSCLC

By: Lauren Harrison, MD, MS
Posted: Wednesday, June 29, 2022

The EGFR kinase inhibitor mobocertinib and the bispecific-antibody amivantamab-vmjw appear to have similar efficacy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) who have exon 20 insertion mutations in EGFR. Sai-Hong Ignatius Ou, MD, PhD, of the University of California, Irvine, presented these results on behalf of colleagues at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9115).

“As each has a different mechanism of action and route of administration, they provide multiple options in the treatment of [exon 20 insertion–mutated EGFR] NSCLC,” concluded the authors. 

This matching-adjusted indirect comparison study compared the overall response rate, duration of response, progression-free survival, and overall survival between mobocertinib and amivantamab. Researchers employed data from a phase I/II study in which patients were treated with 160 mg of mobocertinib daily and compared it with data from a phase I trial in which patients were treated with 1,050 mg of amivantamab. Patients included in the analysis had been previously treated with platinum-based therapies and had exon 20 insertion mutations in EGFR. Differences in baseline characteristics adjusted for in the matching-adjusted indirect comparison study included but were not limited to age, race, sex, smoking status, prior lines of therapy, and time from advanced diagnosis.

The overall survival with mobocertinib was 24.8 months, compared with 22.8 with amivantamab (hazard ratio [HR] = 0.95, 95% confidence interval = 0.55–1.67). The progression-free survival was similar between the groups as well, at 7.4 months with mobocertinib and 8.3 months with amivantamab (HR = 0.82, P = .417). The confirmed overall response rate per an independent review committee was higher with amivantamab (40%) than with mobocertinib (30%), but this was not statistically significant (P = .230). For patients who responded to treatment, the duration of response was numerically higher with mobocertinib (17.5 months) compared with amivantamab (11.1 months), according to the independent reviewers (HR = 0.56, P = .149).

Disclosure: For a full list of authors’ disclosures, visit coi.asco.org.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.